Taken together, these results strongly suggest that RELA and STAT5 co-regulated Bcl-X promoter in response to carboplatin, and conferred chemoresistance in ovarian cancer, in part, through the transcriptional activation of Bcl-xL. The gene discussed is BCL2L1; the disease is ovarian cancer.